# Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes

> **NCT02477475** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1595 (actual)

## Conditions studied

- Reflux Esophagitis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02477475
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-07
- **Primary completion:** 2017-02-20
- **Final completion:** 2017-02-20
- **Target enrollment:** 1595 (ACTUAL)
- **Last updated:** 2017-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02477475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02477475, "Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02477475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*